Oric Pharmaceuticals
Carmen Breslin is an experienced regulatory affairs professional with a strong background in leadership roles across various pharmaceutical companies. Currently serving as Executive Director at ORIC Pharmaceuticals Inc. since April 2019, Carmen previously held positions as Senior Director of Regulatory Operations and Quality. Prior to this, Carmen worked as an Independent Consultant from August 2018 to April 2019 and held multiple roles at IGNYTA, Inc. from June 2015 to July 2018, including Director of Regulatory Operations and Publishing. Carmen also contributed to Seragon Pharmaceuticals, Inc. and Aragon Pharmaceuticals, Inc. as a Senior Manager in Regulatory Affairs and held the position of Regulatory Affairs Manager at Synteract, Inc. from February 2002 to August 2012.
This person is not in any offices
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.